

North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Acentra Health

Quarter 3

SUMMER 2024

In the issue: Website Redesign | Non-Emergent Transportation | Prior Authorization Criteria Updates

Website Redesign

The ND Medicaid PA website has migrated to a new URL. Please save this link for the new landing page: <https://ndmedicaid.acentra.com/>. This website hosts ND Medicaid's preferred drug list (PDL) with coverage criteria, drug PA forms, Drug Use Review (DUR) Board information, and provider education material.

Navigating the New Website

Use the drop-down menus at the top of the screen to navigate the website. Hover your mouse over the arrows for additional drop-down options.

- Drug Coverage
 - Coverage Guidance
 - Covered APIs and OTCs
 - Excluded NDCs for 340b
 - Guidance for Point-of-Sale Rejections
 - Psychotropic Monitoring Program
 - Helpful Links
 - Humana LI NET
 - Medical Codes Requiring Service Authorization (Including Medical Drugs)
 - NADAC Dispute Form
 - SMAC Dispute Form
 - State Medicaid Website
 - Manuals and Guidelines
 - Pharmacy E-mail Archive Link
 - Redirects to archived coverage emails
 - Link also includes a sign-up form to receive future emails
- NDC Drug Lookup
- DUR Board
 - Agenda, handouts, and minutes are posted here for upcoming and historical meetings.
 - Please scroll to the bottom of the webpage to view archived meeting information.
- Education
 - Academic Detailing
 - Newsletters – Newsletters contain coverage and clinical updates. Current and historical newsletters can be found here.

Updated direct links for other important pages are included

- Preferred Drug List (PDL): <https://ndmedicaid.acentra.com/ndpdl/>
- PA forms: <https://ndmedicaid.acentra.com/prior-authorization/#>
- Academic detailing: <https://ndmedicaid.acentra.com/academic-detailing/#academic-detailing>

North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Acentra Health

Non-Emergent Transportation

ND Medicaid covers transportation to covered medical services, including pharmacies. The member should contact their human service zone or tribal office to coordinate transportation. Please keep this in mind for non-adherence to office visits or medication due to transportation issues. For more information regarding the Non-Emergent Medicaid Transportation program:

<https://www.hhs.nd.gov/sites/www/files/documents/Medicaid%20Policies/non-emergency-medical-transportation.pdf>

Prior Authorization (PA) Criteria Updates

The following changes are effective immediately. Updated criteria can be found in the preferred drug list (PDL):

<https://ndmedicaid.acentra.com/ndpdl/>

Diabetes Product Updates

Insulin Updates

- Novolog, insulin aspart, and Apidra (insulin glulisine) require PA. Please transition members on Apidra, Novolog, or insulin aspart to Humalog or insulin lispro to avoid disruption to insulin treatment.
- Fiasp (insulin aspart) does not require PA but does require a 3-month trial of Humalog in claim history.

GLP-1 Agonist Updates: The preferred product placement of the GLP-1 Agonists has been updated.

PREFERRED AGENTS (NO PA REQUIRED)	NON-PREFERRED AGENTS (STEP 1 – PA REQUIRED)	NON-PREFERRED AGENTS (STEP 2 – PA REQUIRED)
VICTOZA (liraglutide)	BYDUREON BCISE (exenatide microspheres)	BYETTA (exenatide)
	OZEMPIC (semaglutide)	liraglutide
	RYBELSUS (semaglutide)	TRULICITY (dulaglutide)

- Victoza Shortage: ND Medicaid will not approve alternative GLP-1 Agonists (including generic liraglutide) due to the Victoza shortage.
 - The alternative GLP-1 Agonist products are already experiencing shortages.
 - GLP-1 Agonists and DPP-4 inhibitors have a very similar mechanism of action.
 - GLP-1 Agonists typically have a long titration period and variable direct switch tolerability, which can contribute to changes in A1c.

Omnipod Updates: ND Medicaid no longer restricts Omnipod coverage by age.

Asthma/COPD Product Updates

Symbicort requires PA. Dulera does not require PA.

- Dulera (which contains formoterol) may be used for SMART (single inhaler for maintenance and rescue therapy) as recommended by the GINA (Global Initiative for Asthma) guidelines.
- The Dulera quantity limit allows up to 2 inhalers per 30 days (not to exceed a total of 9 inhalers per 182 days) for maintenance and rescue utilization.

Lipid-Lowering Agents Updates

Repatha no longer requires PA.

Proton Pump Inhibitor Updates

Dexilant and Konvomep require PA. Members must meet non-solid dosage form criteria as well.

Otic Anti-Infectives

Ciprofloxacin/dexamethasone requires PA.


North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Acentra Health

The “North Dakota Medicaid Pharmacy Program Quarterly News” is a pharmacy newsletter presented by the North Dakota Department of Health and Human Services and published by Acentra Health. This newsletter is published as part of a continuing effort to keep the Medicaid provider community informed of important changes in the North Dakota Medicaid Pharmacy Program.

The North Dakota Department of Health and Human Services has contracted with Acentra Health to review and process prior authorizations (PAs) for medications. For a current list of medications requiring a PA, as well as the necessary forms and criteria, visit <https://ndmedicaid.acentra.com/> or call Acentra Health at (866) 773-0695 to have this information faxed. An important feature on this website is the NDC Drug Lookup, which allows you to determine if a specific NDC is covered (effective date), reimbursement amount, MAC pricing, copay information, and any limitations (prior authorization or quantity limits).

The North Dakota Medicaid Pharmacy Program team appreciates your comments and suggestions regarding this newsletter. To suggest topics for inclusion, please contact Acentra Health at 1-800-225-6998, or e-mail us at ND_Medicaid_Info@acentra.com.



Helpful Numbers

PA Help Desk	866-773-0695
To fax PAs	855-207-0250
To report adverse reactions	800-FDA-1088

Stay Informed:

Quarter 4 Newsletter:

Antimicrobial Stewardship
Ziprasidone and Olanzapine Dosing
Muscle Relaxant Sedation
Metformin Titration

Upcoming DUR Board Meetings:

Wednesday, September 4, 2024 at 1:00 PM